Peru: Relevant Aspects Of Intellectual Property Rights Chapter In The Trans-Pacific Partnership

Last Updated: 11 May 2016
Article by Clarke, Modet & Co Peru

The Trans-Pacific Partnership has an important impact on different business areas, including Intellectual Property , which is developed in Chapter 18 of the multilateral Treaty. Whereas this treaty has generated a great deal of expectation in Peru about intellectual property matters, especially in the patents matters , test data and its impact on the pharmaceutical and biotechnology products TTP. We focus on three important aspects of the TTP.

Regarding Patentable Matter

TTP mentioned in Article 18: 37.1 that "each party shall make the patents available for inventions claimed as at least one of the following: new uses of a known product, new methods of using a known product, or new methods of using a known product. A party may limit such new procedures to vindicate those who do not use the product as such. "

However , Peru being member country of the Andean Community is governed by the rules of the Decisions of the CAN as Decision 486 about Intellectual Property , according to the Resolution of the Andean Court Process 09 -IP- 2014 , makes use preliminary interpretation regarding the uses mentioned : "in conclusion a patent is the solution to a technical problem and that in turn can be protected either as a patent product or process which innovates to respond to the need to be present in the field of industry. However, uses as such are not protected, so that the claims itself , must be clear and defined so that the examiner can itself define what contribution the invention to prior art and thus to decide if it is suitable for protection or not. That is, before the Andean Community uses are not protected subject matter.

If using is allowed, potentially national inventors will be benefited because, according to analysis of indicator of the 2015 Peruvian PTO (INDECOPI) are shown the national applications, the invention patents were 87 versus 197 applications for utility model patents. We can infer that there is more innovation in engineering in Peru. Likewise, the amount of patent application of utility model filed in 2015, 91.6% are national applicants (197 national applications versus 18 foreign applications), ergo there is more improvements in existing technologies (Derived technology) rather than to innovate.

On the other hand in the article 18.37.3 states:  "that a part may be excluded from patentability: (a) diagnostic, therapeutic and surgical methods for treating humans or animals; (b) plants and animals other than micro-organisms, and essentially biological processes for the production of plants or animals other than non-biological and microbiological processes. However, in accordance with paragraph 1 and without prejudice to paragraph 3, each party confirms that patents shall be available at least for inventions derived from plants. "

These articles are in accordance with the provisions of Article 27.3 paragraphs a and b, respectively, the TRIPS Agreement in which the power was provided to the Member Country exclude patentability these matters, which was also taken at the time by the Regional Policy of the Andean Community under Article 20 of Decision 486, standard governing Peru on Intellectual Property.

Taking into consideration the article Article 20 of Decision 486 excludes patentable plant subject matter, Peru as a member of UPOV ( International Union for the Protection of New Varieties of Plants ) should be given a system of protection of plant varieties improved . This sui generis patent system is called " Breeder´s Rights Protection ", which is regulated by Decision 345 of the CAN and in accordance with Article 27.3 b of the TRIPS: ""Plants and animals (...) " Members shall provide for the protection of plant varieties either by patents or by an effective sui generis system or by any combination thereof"

To date Peru has implemented these exclusions and sui generis protection systems in accordance with the TRIPS Agreement, Decision 486 and Decision 345. In that sense, one could say that the only "real" change in patentable subject matter. It is that through the treaty TPP would be protectable new uses, new methods or procedures of a product , which could fall on a machine or composition. However, Peru will have to request opinion from the CAN before applying this article of the treaty.

Regarding the pharmaceutical related measures - Unreasonable adjustment

The measures " Unreasonable adjustment" in the patents are taking place in our country since the Legislative Decree No. 1075 referred to in Article 32 that "The competent leadership , exclusively at the request of a party" shall adjust the patent term where an unreasonable delay has occurred in the granting process, except where the patent is for a pharmaceutical product or procedure. With the TPP this measure would also apply to pharmaceutical products". With the APTA this measure would also apply to pharmaceutical products , according to what is mentioned in Article 18.48.1 : "With respect to a pharmaceutical product that is subject to a patent, each Party shall provide to within one adjust patent to compensate the owner for unreasonable reductions to the effective patent term resulting from the marketing approval process:

Also, Decision 486 - Common Regime on Industrial Property, in conformity with its amendment Decision 689, Chapter V, Title II on patents provides that with the exception of pharmaceutical  patents, to establish the means to compensate the patent owner for unreasonable delays in the National Office in issuing it, restoring the terms or patent rights. Member Countries deemed unreasonable delays superior to five years from the date of filing the patent application or three years from the request for examination of patentability, as long as the periods attributable to actions of the patent applicant are not included in the determination of such delays.

Whereas Decision 486, Andean law governing the Peruvian patent system provides that unreasonable delay settings do not apply to pharmaceutical patents, and unlike the APTA provides that if these should be applied to pharmaceutical patents. Peru shall request the opinion of the Andean Community on the applicability of this provision, as mentioned in Annex 18-D , in order to avoid defaulting on agreements made : "Under the Andean Decision 486, Common Regime of Industrial Property and the Decision 689, Adequacy of certain articles of Decision 486, restricts Peru to implement its obligations under the Article 18.48.2 (Setting the patent term for unreasonable delays), Peru commits to make its best efforts to obtain a waiver from the Andean Community that allows it to in a manner consistent with Article 18.46.3 ( ... ) ".

Protection of test data or other undisclosed - Biological Products

To date, the Legislative Decree No. 1072 is the standard that regulates the protection of test data and other undisclosed Pharmaceutical, pointing through its Article 3: "No other person other than that whom submitted the undisclosed test data needed to determine the safety and efficacy of a product may, without the consent of such person, use such data to support an application for approval of a health record for the period of protection normally be five years".

It is worth mentioning that the D.L. 1072 only applies to pharmaceuticals chemical, so the "Test Data Protection " of biological products are not covered by this standard..

About the APTA in Article 18.51 states that "A Party shall either: ( A) with respect to the first marketing authorization in a Party of a new pharmaceutical product is or contains a biological protection have effective commercial implementation of Article 18.50.1 (Protection of test data or other undisclosed data ) and Section 18.50.3 , mutate mutandis , for a period of at least eight years from the date of first marketing authorization for that product in that Party; or alternatively ( B ) with respect to the first marketing authorization in a Party of a new pharmaceutical product it is or contains a biological , having effective trademark protection : ( i ) through the implementation of Article 18.50.1 (Protection of test data or other undisclosed data and Section 18.50.3 , mutatis mutandis , for the period of at least 5 years from the date of first marketing authorization product in that Party , ( ii ) through other measures , and ( iii ) recognizing that business conditions also contribute to effective trade protection to provide comparable results in the market.

In this sense, it is decision of the signatory to choose one of the options described. Thus , in the case of Peru to be an importer of drugs , perhaps the best adaptation option is literal ( B ) arising from the treaty, that is, provide five years of protection for test data of biological products as is currently being done with data from test chemicals, provided that previously fit their business conditions.

It is clear that the Data Protection Test is not an extension of protection of the patent system, but is another form of protection for results from clinical trials and not to the invention as such, as in the case of patents.

Regarding biosimilars, the TTP only mentions the regulation of test data more biotech products does not regulate the parameters of acceptance or not these. So it is the prerogative of each country regulation. What happens in Peru is that to date there is no directive regulating the entry of biosimilar; Peru does not have a standard to establish the parameters for assessing these drugs with the reference biological product.

Finally , pursuant to Article 18.53.1 the TPP states: " If a Party permits , as a condition of the marketing authorization of a pharmaceutical product, other than the one who originally submitting safety and efficacy, based on evidence or information concerning the safety and efficacy of which was previously authorized product , such as evidence of prior marketing authorization by the Party or in another territory , that Party shall provide : "a system that gives notice to the holder of the patent or to allow the patentee to be notified , prior to the marketing of the pharmaceutical product that the other person is looking to market that product during the term of the applicable patent covering the licensed product or method of use authorized". Consequently, the TTP requires Peru to implement a system in which to link the information of the patent system (INDECOPI ) and the marketing authorizations of medicines ( DIGEMID ) .

Originally published March 2016

Clarke, Modet & Co - PERU

Av. Conquistadores N°1136, Oficina 304, Lima 27
Tel: +51 1 461 20 73

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions